



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

## \*CORRESPONDENCE

Lujun Zhao  
✉ zhaolujun@tjmuch.com  
Jinlong Song  
✉ jls7286@163.com

<sup>†</sup>These authors have contributed equally to this work

RECEIVED 06 August 2025

ACCEPTED 07 August 2025

PUBLISHED 19 August 2025

## CITATION

Li J, Li Y, Zhong J, Du J, Chen J, Shi J, Zhao L and Song J (2025) Correction: Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas. *Front. Immunol.* 16:1681008. doi: 10.3389/fimmu.2025.1681008

## COPYRIGHT

© 2025 Li, Li, Zhong, Du, Chen, Shi, Zhao and Song. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Correction: Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas

Jinpeng Li<sup>1,2†</sup>, Yuanming Li<sup>3†</sup>, Jingtao Zhong<sup>4†</sup>, Jiasheng Du<sup>5</sup>, Jiao Chen<sup>2</sup>, Jutian Shi<sup>2</sup>, Lujun Zhao<sup>1\*†</sup> and Jinlong Song<sup>2\*†</sup>

<sup>1</sup>Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China, <sup>2</sup>Department of Interventional Therapy I, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China, <sup>3</sup>Interventional Vascular Department, Laizhou Hospital of Traditional Chinese Medicine, Laizhou, Shandong, China, <sup>4</sup>Department of Hepatobiliary Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China, <sup>5</sup>Graduate Department of Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China

## KEYWORDS

hepatocellular carcinoma, high-flow hepatic arteriovenous fistula, hepatic arterial infusion chemotherapy, immune checkpoint inhibitors, tyrosine kinase inhibitors

## A Correction on

**Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas**

By Li J, Li Y, Zhong J, Du J, Chen J, Shi J, Zhao L and Song J (2025) *Front. Immunol.* 16:1643290. doi: 10.3389/fimmu.2025.1643290

Author “Lujun Zhao” was erroneously spelled as “Luzhun Zhao”.

The original version of this article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.